Danaher plans unveiling at ADLM 2026
July 28, 2026—At ADLM 2026, Danaher companies will come together to unveil the next generation of diagnostic innovation.
Webinars and Commercial Conversations — Register Now
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Pictor Holdings debuts PictImager at ADLM 2026
July 27, 2026—Pictor Holdings is debuting at ADLM 2026 its next-generation high-resolution platform, the PictImager, for research use only.
Seegene analysis shows limits of single-pathogen respiratory testing
July 27, 2026—Seegene has released findings from an analysis of approximately 260,000 pediatric respiratory PCR test results collected over 42 months from children aged zero to five years.
Siemens Healthineers adds capillary testing menu to Atellica analyzers
July 27, 2026—Siemens Healthineers has launched capillary testing on the Atellica CH, IM, and CI analyzers after receiving the CE mark for 24 capillary blood testing claims.
ARUP launches multiple myeloma MRD assay by spectral flow cytometry
July 24, 2026—ARUP Laboratories has launched the ARUP Clarispect Multiple Myeloma MRD by Spectral Flow Cytometry.
Seegene USA gets EUA for HSV, VZV, mpox assay
July 23, 2026—Seegene USA has received FDA emergency use authorization for the Allplex HSV-1&2/VZV/MPXV assay.
Cepheid to unveil third-generation GeneXpert at ADLM 2026
July 22, 2026—Cepheid will unveil the third generation of the GeneXpert system on Tuesday, July 28, at the Association for Diagnostics and Laboratory Medicine Annual Scientific Meeting.
FSP 5th Multidisciplinary Interactive Precision Medicine Symposium
July 21, 2026—The Florida Society of Pathologists 5th Multidisciplinary Interactive Precision Medicine Symposium will take place Aug. 22 at Moffitt Cancer Center, 12902 USF Magnolia Drive, in Tampa, Fla.
Zepto introduces FungiFlex Pneumocystis jirovecii, Mold Plus tests
July 20, 2026—Zepto Life Technology has introduced FungiFlex Pneumocystis jirovecii, a targeted plasma cell-free DNA liquid biopsy assay for the detection of P. jirovecii, and the FungiFlex Mold Plus panel, which combines invasive mold detection with P. jirovecii in a single plasma-based test order.
Leica Biosystems to acquire StatLab Medical Products
July 15, 2026—Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products, a global developer and manufacturer of anatomic pathology products, from Linden Capital Partners and Audax Private Equity. Following the closing, StatLab will become part of Leica Biosystems. StatLab provides a broad portfolio of products across the preanalytical and analytical histology workflow, from specimen collection and tissue processing through slide preparation and staining. Built on a strong reputation for